Michelson E L, Frishman W H
Ann Intern Med. 1983 Oct;99(4):553-5. doi: 10.7326/0003-4819-99-4-553.
Labetalol, a new beta-adrenoceptor blocking drug with ancillary alpha-adrenoceptor blocking and vasodilating activity, will soon be available in the United States for the treatment of hypertension. Labetalol is effective in the acute management of hypertensive emergencies, as well as the long-term treatment of mild and moderate hypertension. In combination with a diuretic agent, labetalol is also effective in controlling moderate and severe hypertension. Efficacy for other indications is under investigation. Labetalol is generally well tolerated. Side effects typical of beta-blockers are less prominent with labetalol in the usual antihypertensive doses of 100 mg to 1200 mg twice daily. However, occasional mild vasodilating, alpha-blocking, and other nonspecific effects are best managed with careful dose titration.
拉贝洛尔是一种新型β肾上腺素能受体阻断药物,具有辅助性α肾上腺素能受体阻断和血管舒张活性,很快将在美国上市用于治疗高血压。拉贝洛尔在高血压急症的急性处理以及轻度和中度高血压的长期治疗中均有效。与利尿剂联合使用时,拉贝洛尔在控制中度和重度高血压方面也有效。其对其他适应症的疗效正在研究中。拉贝洛尔一般耐受性良好。在通常每日两次100毫克至1200毫克的抗高血压剂量下,拉贝洛尔引起的典型β受体阻滞剂副作用不那么突出。然而,偶尔出现的轻度血管舒张、α阻断及其他非特异性效应,最好通过仔细的剂量滴定来处理。